Breast Cancer Clinical Trials in Portland

Showing 21-40 of 185 trials

MammoScreen Breast Cancer Risk Assessment and Decision Aid for Breast Cancer Screening and Referrals

NCT04996316

This study collects information to implement MammoScreen for Breast Cancer Screening and Referrals. MammoScreen is a risk assessment questionnaire that identifies individuals at average and increased risk for breast cancer and guides their screening decisions.

Breast Carcinoma

OHSU Knight Cancer Institute1,141 participantsStarted Sep 2022

Portland, Oregon, United States

ACTIVE_NOT_RECRUITINGPHASE3< 1 mile

S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer

NCT01674140

RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using tamoxifen citrate, goserelin acetate, leuprolide acetate, anastrozole, letrozole, or exemestane, may fight breast cancer by lowering the amount of estrogen the body makes. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet know whether hormone therapy is more effective when given with or without everolimus in treating breast cancer. PURPOSE: This randomized phase III trial studies how well giving hormone therapy together with or without everolimus work in treating patients with breast cancer.

Breast Cancer

SWOG Cancer Research Network1,939 participantsStarted Sep 2013

Birmingham, Alabama, United States • Anchorage, Alaska, United States • Anchorage, Alaska, United States +1456 more locations

MammoScreen Breast Cancer Risk Assessment and Decision Aid for Breast Cancer Screening and Referrals

S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer

Breast Cancer Trials in Other Cities

Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

A Study of MGC026 in Participants With Advanced Solid Tumors

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

A Phase 1/1b Study of IAM1363 in HER2 Cancers

Using FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE Study

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)

Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients

Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer

A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer

Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer

A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer

Randomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients With Oligoprogressive Metastatic Cancers of the Breast and Lung

A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer

EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)

Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors

Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study

Other Conditions in Portland